MTOR and prostate carcinoma: Using animal models of prostate cancer, as well as primary cancer samples, it was shown that SPOP mutation activates both PI3K/mTOR and androgen receptor signaling, efficiently uncoupling the normal feedback occurring between these two pathways and through this mechanism promoting prostate cancer development [135].